Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

2.1 Moderate Growth Is Projected for the CMV Market from 2017 to 2027
2.2 Manufacturers Are Focusing on Novel CMV Prophylactic Strategies with Less Toxicity
2.3 Significant Unmet Need Remains for Products to Prevent Congenital CMV Infections
2.4 Opportunities Exist for Long-Term and Cost-Effective Prophylaxis Therapies
2.5 Diverse Pipeline Therapies Poised to Begin Addressing Unmet Needs
2.6 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 CMV Disease in Diagnosed Prevalent HIV Patients
5.3.2 CMV Disease in SOT Patients
5.3.3 CMV Disease in HSCT Patients
5.3.4 Congenital CMV Disease
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for CMV (2017-2027)
5.5.1 Diagnosed Incident Cases of CMV
5.5.2 Age-Specific Diagnosed Incident Cases of CMV
5.5.3 Sex-Specific Diagnosed Incident Cases of CMV
5.5.4 CMV Diagnosed Incident Cases by Population at Risk
5.5.5 HIV-CMV
5.5.6 SOT Patients
5.5.7 SOT-CMV
5.5.8 HSCT Patients
5.5.9 HSCT-CMV
5.5.10 Diagnosed Incident Cases of Congenital CMV
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6.1 Overview

7.1 Overview
7.2 Treatment Options for Resistant or Refractory CMV Infections
7.2.1 Unmet Need
7.2.2 Gap Analysis and Opportunity
7.3 A Safe and Immunogenic Vaccine for CMV Prevention
7.3.1 Unmet Need
7.3.2 Gap Analysis and Opportunity
7.4 Antiviral Monotherapy or Combination Therapy with Improved Efficacy and Safety
7.4.1 Unmet Need
7.4.2 Gap Analysis and Opportunity
7.5 Prevention and Management of Congenital CMV Infections
7.5.1 Unmet Need
7.5.2 Gap Analysis and Opportunity
7.6 Tools or Biomarkers to Assess Risk of Reactivation
7.6.1 Unmet Need
7.6.2 Gap Analysis and Opportunity

8.1 Overview
8.1.1 Development of Antivirals with Novel MOAs to target refractory or resistant CMV
8.1.2 Application of cellular immunotherapy
8.1.3 Development of a CMV Vaccine
8.1.4 Immune Globulin and mAb Therapies
8.2 Clinical Trial Design
8.2.1 Antivirals
8.2.2 Cellular Immunotherapy
8.2.3 Vaccines
8.2.4 Immune Globulins

9.1 Overview
9.2 Innovative Early-Stage Approaches

10.1 Clinical Benchmark of Key Pipeline Products
10.1.1 Therapeutic Agents
10.1.2 Prophylactic Agents
10.2 Commercial Benchmark of Key Pipeline Products
10.2.1 Therapeutic Agents
10.2.2 Prophylactic Agents
10.3 Competitive Assessment
10.3.1 Therapeutic Agents
10.3.2 Prophylactic Agents
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan

11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 CMV Patient Population Segmentation
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research - KOLs Interviewed for This Report
11.4.1 KOLs
11.5 Primary Research - Prescriber Survey
11.6 About the Authors
11.6.1 Analyst
11.6.2 Therapy Area Director
11.6.3 Epidemiologist
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About
11.8 Contact Us
11.9 Disclaimer

Table 1: CMV: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbidities for CMV
Table 3: Treatment Guidelines for CMV
Table 4: Leading Treatments for CMV, 2018
Table 5: Clinical Trial Designs for CMV Pipeline Antivirals
Table 6: Clinical Trial Designs for CMV Cellular Immunotherapy
Table 7: Clinical Trial Designs for CMV Vaccines
Table 8: Clinical Trial Designs for CMV Immune globulins
Table 9: Innovative Early-Stage Approaches for CMV, 2018
Table 10: Clinical Benchmark of Key Pipeline Therapeutics - CMV
Table 11: Clinical Benchmark of Key Pipeline Prophylactics - CMV
Table 12: Commercial Benchmark of Key Pipeline Therapeutics - CMV
Table 13: Commercial Benchmark of Key Pipeline Prophylactics - CMV
Table 14: Key Events Impacting Sales for CMV, 2017-2027
Table 15: CMV Market - Global Drivers and Barriers, 2017-2027
Table 16: Key Historical and Projected Launch Dates for CMV
Table 17: Key Historical and Projected Patent Expiry Dates for CMV
Table 18: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for CMV in 2017 and 2027
Figure 2: Competitive Assessment of the Marketed and Pipeline Therapeutics Benchmarked Against the SOC, Ganciclovir and Valganciclovir.
Figure 3: Competitive Assessment of the Marketed and Pipeline Prophylactics Benchmarked Against the Standard of Care (SOC), Ganciclovir and Valganciclovir.
Figure 4: Human CMV Virion Structure
Figure 5: CMV Life Cycle in a Human Cell
Figure 6: Age-Standardized Diagnosed Incidence of CMV Disease, All Ages, 2017
Figure 7: Case Flow Map
Figure 8: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of HIV-CMV
Figure 9: Sources Used and Not Used for Calculations of SOT Patients
Figure 10: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of SOT-CMV
Figure 11: Sources Used and Not Used for Calculations of HSCT Patients and Diagnosed Incident Cases of HSCT-CMV
Figure 12: Sources Used and Not Used for Calculations of Live Births and cCMV Cases
Figure 13: Diagnosed Incident Cases of CMV, 7MM, Men and Women, All Ages, 2017
Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of CMV Disease, Men and Women, 2017
Figure 15: 7MM, Sex-Specific Diagnosed Incident Cases of CMV Disease, All Ages, 2017
Figure 16: 7MM, Diagnosed Incident Cases of CMV Disease by Population at Risk, Men and Women, All Ages, 2017
Figure 17: 5EU and Japan, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017-2027
Figure 18: US, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017-2027
Figure 19: 7MM, SOT Patients, Men and Women, All Ages, 2017-2027
Figure 20: 7MM, Diagnosed Incident Cases of SOT-CMV, Men and Women, All Ages, 2017-2027
Figure 21: 7MM, HSCT Patients, Men and Women, All Ages, 2017-2027
Figure 22: 7MM, Diagnosed Incident Cases of HSCT-CMV, Men and Women, All Ages, 2017-2027
Figure 23: 5EU and Japan, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017-2027
Figure 24: US, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017-2027
Figure 25: Unmet Needs and Opportunities in CMV
Figure 26: Overview of the Development Pipeline in CMV
Figure 27: Key Phase II/III Trials for the Promising Pipeline Agents that Author Expects be Licensed for CMV in the 7MM During the Forecast Period
Figure 28: Competitive Assessment of the Marketed and Pipeline Therapeutics Benchmarked Against the SOC, Ganciclovir and Valganciclovir.
Figure 29: Competitive Assessment of the Marketed and Pipeline Prophylactics Benchmarked Against the SOC, Ganciclovir and Valganciclovir.
Figure 30: Global (7MM) Sales Forecast by Country for CMV in 2017 and 2027
Figure 31: Global Sales Forecast by Product for CMV in 2017 and 2027
Figure 32: Therapeutic Sales Forecast for CMV in the US in 2017 and 2027
Figure 33: Prophylactic Sales Forecast for CMV in the US in 2017 and 2027
Figure 34: Therapeutic Sales Forecast for CMV in the 5EU in 2017 and 2027
Figure 35: Prophylactic Sales Forecast for CMV in the 5EU in 2017 and 2027
Figure 36: Therapeutic Sales Forecast for CMV in Japan in 2017 and 2027
Figure 37: Prophylactic Sales Forecast for CMV in Japan in 2017 and 2027 121